I don't dispute the evidence the Mastitis is a $50 billion dollar global problem. The key question is what revenue POH can realistically expect to generate?
Anyone that has followed bio companies know they all engage in the the 'it's a xx billion dollar market' game, but the revenue available to them is only a fraction of that "potential" What do people think POH can generate in its first year (Sep 11 - Sep 12)? I doubt they could do more than $1m at best.
I don't dispute the evidence the Mastitis is a $50 billion...
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.508M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6.592K | 2.204M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 53 | 96714175 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 19678077 | 12 |
View Market Depth
| Last trade - 15.57pm 21/06/2024 (20 minute delay) ? |
| AVE (ASX) Chart |